NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Smith on Stocks highlights so far...

Larry points out that Trump's emphasis on "the Right to Try" for terminally ill cancer patients in his recent SofU speech forecasts positive implications for DCVax-L and possibly DCVax-Direct as they draw "close to completing a phase 3 trial in GBM." I know we've been hoping that the company will opt to complete the trial sometime soon, the fact that Larry thinks this as well makes me think this may actually finally be the real deal.

From Larry's perspective, he also suggests that it can be difficult to predict how long will take to get a 65 co-authored article into a peer-reviewed journal.

The trial is ongoing so that these conclusions are based on blinded data. I am expecting the publication of a manuscript on the blinded data in a peer reviewed journal in a matter of perhaps a month or two. The timing is difficult to predict as the editing process involves a lot of participants. It is co-authored by about 65 investigators in the trial. This manuscript could/ should enhance the argument that DCVax-L is producing a long term survival tail that could represent a major advance in the treatment of glioblastoma. If so, this would be one of the most amazing stories in the history of biotechnology. ~ Larry Smith

And I like Larry's comparison of NWBO to David against the wolfpack (Goliath).

The manipulation of the stock by the wolfpack has resulted in NWBO being priced as though there were no chance of success for DCVax-L in its phase 3 trial. A vicious social media campaign has had great success in portraying NWBO as being a stock promotion and a criminal enterprise pumping worthless technology. Against this brutal onslaught, NWBO management has been able to nearly complete the phase 3 trial although for a time, bankruptcy could not be dismissed out of hand. This has been a “David versus wolfpack” accomplishment. ~ Larry Smith

https://smithonstocks.com/2198-2/